SecBot SecBot
8-K ·Filed Apr 27, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001104659-26-049434
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine administrative filing with no material new information. Monitor subsequent filings for actual equity grant details or shareholder vote outcomes, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$93.83
T+0 close · Apr 27, 2026 · via day close
Latest settled
+7.38%
T+60 · $100.75
Vs SPY
+3.66%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $93.83entry
  2. T+1 · 7mo ago −1.48%α −1.47% · $92.44
  3. T+5 · 7mo ago −6.70%α −8.39% · $87.54
  4. T+20 · 6mo ago −7.63%α −13.10% · $86.67
  5. T+60 · 4mo ago +7.38%α +3.66% · $100.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abbott Laboratories filed an 8-K reporting the adoption of amended and restated bylaws effective April 24, 2026 (Item 5.03) and provided standard form equity award agreements under the 2026 Incentive Stock Program (Exhibits 10.23 and 10.18). No material financial data, officer changes, or shareholder vote results were disclosed. The filing is routine and has no immediate trading implications.

Key Facts

  • Amended and restated bylaws adopted effective April 24, 2026.
  • Non-Qualified Stock Option Agreement and Performance Restricted Stock Unit Agreement forms filed as exhibits (placeholder terms).
  • No actual grant amounts, exercise prices, or performance targets disclosed.
  • Shareholder votes occurred (Item 5.07) but results not provided in filing.

Financial Impact

No financial impact estimable from filing; placeholder amounts for equity awards not specified.

Risk Factors

  • None from this filing; potential future dilution if equity grants are large, but amounts unknown.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
74% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-049434
Document: tm2612318d1_ex10-23.htm0001104659-26-049434
Document: tm2612318d1_ex10-18.htm0001104659-26-049434

Track record

38 reports on ABT

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +17.16% at T+20 after the Jul 1, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $108.52 −1.28% settles Dec 7
  2. Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $108.52 +5.26% settles Nov 24
  3. Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $108.52 +5.73% settles Nov 25
  4. Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $108.52 +5.86% settles Nov 19
  5. Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
  6. Oct 21, 202626d ago 8-K Bearish 6/10 No price data
  7. Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
  8. Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $108.52 +7.97% settles Nov 18
  9. Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $108.52 +4.29% ▲ +3.26% +6.72% vs SPY
  10. Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $108.52 +3.46% ▲ +3.46% +4.62% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026